Omeros Corporation

333 articles with Omeros Corporation

• Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA

  2/14/2019

  Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required

• Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors

  2/12/2019

  Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline

• Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

  1/17/2019

  Additional Positive Data Reported from Second Cohort in Phase 2 Trial

• Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018

  1/14/2019

  Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations

• Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy

  12/20/2018

  Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research

• Omeros Announces Research Collaboration with University of Cambridge

  12/11/2018

  Newly Established Center Will Focus on Complement and Inflammation

• Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

  12/6/2018

  EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review

• Omeros Announces Additions to Senior Management Team

  12/3/2018

  Hires Commercial and CMC Heads from Celgene

• Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

  11/8/2018

  Omeros Corporation today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933

• Omeros Corporation Reports Third Quarter 2018 Financial Results

  11/8/2018

  Conference Call Friday, November 9th at 8:30 a.m. ET

• Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018

  11/5/2018

  Omeros Corporation today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.

• FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

  10/23/2018

  OMS721 now with orphan designation covering both prevention and treatment of HSCT-TMA in U.S. and in Europe

• Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®

  10/1/2018

  CMS’ Separate Payment for Cataract Surgery Drug Resumes Today

• 

  BioSpace Online Community Shares Job Openings With Industry Colleagues Who Lost Jobs

  9/11/2018

  Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.

• European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation

  8/28/2018

  Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).

• Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference

  8/10/2018

  Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, August 14, 2018 at 2:30 p.m. EDT.

• Omeros Corporation Reports Second Quarter 2018 Financial Results

  8/9/2018

  Conference Call Today at 4:30 p.m. ET

• Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018

  8/3/2018

  Omeros Corporation announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.

• Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer

  8/2/2018

  Company Expands Leadership to Keep Pace with Advancing Pivotal Clinical Programs

• Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire

  7/26/2018

  With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation